Increase in Th17 and T-reg lymphocytes and decrease of IL22 correlate with the recovery phase of acute EAE IN rat by Almolda Ardid, Beatriz et al.
Increase in Th17 and T-reg Lymphocytes and Decrease of
IL22 Correlate with the Recovery Phase of Acute EAE IN
Rat
Beatriz Almolda1*, Manuela Costa2, Maria Montoya3, Berta Gonza´lez1, Bernardo Castellano1
1Unit of Histology, Department of Cell Biology, Physiology and Immunology, Institute of Neuroscience. Universitat Auto`noma de Barcelona, Bellaterra, Spain, 2 Servei de
Cultius Cel.lulars, Produccio´ d’Anticossos i Citometria. Universitat Auto`noma de Barcelona, Bellaterra, Spain, 3Centre de Recerca en Sanitat Animal, UAB-IRTA, Campus de
la Universitat Auto`noma de Barcelona, Bellaterra, Barcelona, Spain
Abstract
Experimental autoimmune encephalomyelitis (EAE), a well-established model of multiple sclerosis, is characterised by
microglial activation and lymphocyte infiltration. Induction of EAE in Lewis rats produces an acute monophasic disease
characterised by a single peak of disability followed by a spontaneous and complete recovery and a subsequent tolerance
to further immunizations. In the current study we have performed a detailed analysis of the dynamics of different
lymphocyte populations and cytokine profile along the induction, peak, recovery and post-recovery phases in this
paradigm. MBP-injected rats were sacrificed attending exclusively to their clinical score, and the different populations of T-
lymphocytes as well as the dynamics of different pro- and anti-inflammatory cytokines were analysed in the spinal cord by
flow cytometry, immunohistochemistry and ELISA. Our results revealed that, during the induction and peak phases, in
parallel to an increase in symptomatology, the number of CD3+ and CD4+ cells increased progressively, showing a Th1
phenotype, but unexpectedly during recovery, although clinical signs progressively decreased, the number and proportion
of CD3+ and CD4+ populations remained unaltered. Interestingly, during this recovery phase, we observed a marked
decrease of Th1 and an important increase in Th17 and T-reg cells. Moreover, our results indicate a specific cytokine
expression profile along the EAE course characterized by no changes of IL10 and IL17 levels, decrease of IL21 on the peak,
and high IL22 levels during the induction and peak phases that markedly decrease during recovery. In summary, these
results revealed the existence of a specific pattern of lymphocyte infiltration and cytokine secretion along the different
phases of the acute EAE model in Lewis rat that differs from those already described in chronic or relapsing-remitting mouse
models, where Th17-cells were found mostly during the peak, suggesting a specific role of these lymphocytes and cytokines
in the evolution of this acute EAE model.
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Introduction
Experimental autoimmune encephalomyelitis (EAE) is a useful
animal model for the study of multiple sclerosis (MS) that is
produced by the immunisation of susceptible animals with myelin
proteins. Among the different EAE models, immunisation of
susceptible Lewis rats with Myelin Basic Protein (MBP) induced an
acute monophasic disease characterised by weight loss and
hindlimb paralysis, followed by a spontaneous recovery, after
which animals became resistant to further immunisations with
MBP [1,2]. This EAE model is of special interest because provides
a unique tool to study the cellular and molecular mechanisms
involved not only in the induction of the disease, but more
interestingly, those participating in the recovery process and the
establishment of immunological tolerance.
Although there are a wide number of studies published about
different aspects of EAE in Lewis rats, the major part of these
studies are focused on specific time-points, mainly at the peak of
the disease, whereas molecular and cellular changes taking place
during the induction and recovery phases remain poorly defined.
To address this lack of information and gain insights into the
mechanisms involved in the initiation and resolution of the
pathological process, in the last years we have performed a series
of detailed studies in which animals were sacrificed attending
exclusively to their clinical score along the different phases
characteristics of this model. In these studies we have reported
changes in the morphology and phenotype of microglial cells, in
terms of antigen presenting capacity, along the different phases of
EAE showing that during the induction and peak phases,
microglia exhibited a phenotype of immature dendritic cells,
characterised by MHC-class I and class-II expression, no co-
stimulatory molecules and CD1 expression, whereas during the
recovery and even post-recovery phases, activated microglia
maintained MHC expression and a subpopulation of cells
expressed B7.2 [3] and/or CD4 [4].
In addition to microglial reactivity it is well established that T-
cell infiltration is a crucial feature of EAE [5]. Specifically, CD4+
Th1 cells are widely accepted as the key players in leading to the
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immune response associated with EAE [6]. However, in the last
years, upon the emergence of new subsets of CD4+ T-cells with
different cytokine profiles and functions [7,8,9], this classical
assumption has been reconsidered and nowadays it is suggested
that, in addition to Th1 cells, other subtypes of CD4+ T-cells may
also be involved in EAE pathogenesis. Indeed, it has recently been
demonstrated that injection of Th17 lymphocytes, a new
characterised subset of CD4+ T-cells [10,11], are able to induce
EAE in mice [12]. Moreover, accumulation of T-regulatory
Foxp3+ cells (T-regs) was reported within the mouse CNS
concurrent with EAE recovery [13,14,15]. Although an important
number of reports can be found in the literature about infiltration
of T-cells in different EAE models [16,17,18,19,20,21,22,23], it is
important to take into account that major part of these studies are
focused specially in the peak of the disease, and do not
characterized the different subtypes of T-cells in the induction
and recovery phases. Moreover, some of these studies analysed
only changes occurring in lymphatic organs, especially spleen and
lymph nodes [17,19], or described changes in the CD4+T-cell
population but not in the subtypes of these cells [16,21,22,23].
Nevertheless, little is known about the dynamics of the specific
lymphocyte subtypes inside the spinal cord along the course of the
disease.
In this way, the aim of the present study was to perform a
careful analysis of CD4+ T-cell subsets dynamics and their
cytokine profile along the induction, peak, recovery and post-
recovery phases in the acute EAE model induced in Lewis rats.
Our results indicate that the population of T-cells remained
unaltered during all the phases of the acute EAE but showing
specific phenotypes during the induction and recovery phases.
Interestingly, and in contrast to studies in EAE mice models, in
this acute model the population of Th17 cells was higher during
the recovery phase.
Materials and Methods
Ethics Statement
All experimental animal work was conducted according to
Spanish regulations in agreement with European Union directives
(86/609/CEE, 91/628/CEE i 92/65/CEE) and was approved by
the Ethical Committee of the Autonomous University of Barcelona
(CEEA-UAB 569).
Animals and EAE induction
A total of 140 female Lewis rats (180 g/200 g) susceptible to
develop experimental autoimmune encephalomyelitis (EAE) were
purchased from Charles River (France) and maintained with food
and water ad libitum in a 12 h light/dark cycle.
EAE was induced by the injection in both hindlimbs of an
emulsion containing 100 mg myelin basic protein (MBP) (Sigma,
USA, Ref. M2295) in Complete Freud’s Adjuvant (CFA) (Ref.
0638; Difco; USA) and 0.2 mg of Mycobacterium tuberculosis (M.
tuberculosis) H37 Ra (Ref. 3114; Difco; USA). Animals injected with
vehicle solution were used as control (sham).
The presence of clinical signs was evaluated daily in all animals,
using the following clinical score test: 0, no clinical signs; 0.5,
partial loss of tail tonus; 1, tail paralysis; 2, paraparesis of hindlimb;
3, paraplegia; 4, tetraparesis; 5, tetraplegia and 6, death. Paralysed
animals were afforded easier access to food and water.
Experimental groups
As in previous studies [3,4], EAE-induced animals were
sacrificed according to their clinical score, at different phases
along the EAE course, as detailed: 1) before the appearance of
symptomatology (2, 4, 6 and 8 days post-immunisation); 2) during
the induction phase: at score 0.5, score 1 and score 2; 3) at the
peak of the disease (score 3); 4) during the recovery phase: at score
2 of recovery (score 2R), score 1 of recovery (score 1R) and 0 of
recovery (score 0R) and 5) during the post-recovery phase, at 28,
32, 40 and 90 days post-immunisation (referred to as score 0R–
28dpi, score 0R–32 dpi, score 0R–40 dpi and score 0R–90 dpi). A
total of 56 EAE-induced rats and 7 shams injected with vehicle
were used for flow cytometry and ELISA studies. For immuno-
histochemistry, 68 EAE-induced rats and 9 sham animals were
processed.
Flow cytometry analysis
As already described in previous studies [4], for flow cytometry
analysis, animals were anesthetised with 0.015 ml/g ketamine
(80 mg/kg)/xylazyne (10 mg/kg) and intracardially perfused with
phosphate buffer solution (PBS). Quickly, the entire spinal cord
was dissected out and the meninges were carefully removed. In
order to obtain cell suspensions, tissue was dissociated through
meshes of 140 mm and 70 mm and digested with a mixture of
DNase I (28 U/ml; 10 104 159 001; Roche) and collagenase
(0.2 mg/ml; LS004194, Worthington). Subsequently, each cellular
suspension was centrifuged for 20 min at 600 g at room
temperature in a discontinuous-density Percoll gradient (17-
0891-02; Amersham-Pharmacia) between 1.08 g/ml and 1.03 g/
ml. Myelin in the upper layer was removed. Cells in the interphase
and in the upper-phase were collected, washed in PBS +2% serum
and labelled during 30 min at 4uC with different combinations of
the following surface markers: anti-CD4-PECy5 (1:400; 554839;
BD Pharmingen; San Diego, CA), anti-CD4-APC.Cy7 (1:400;
201518; Biolegend), anti-CD3-FITC (1:400; 557354; BD Phar-
mingen, San Diego, CA), and anti-CD45RC-PE (1:400; 554888;
BD Pharmingen, San Diego, CA). Subsequently, for the detection
of intracellular markers, samples were permeabilised for 40 min
using the Foxp3 staining buffer set (00-5523-00; eBiosciences; San
Diego, CA) and labelled for 30 min at 4uC with anti-Tbet-
PerCP.Cy5.5 (1:400; 45-5825; eBiosciences; San Diego, CA), anti-
GATA3-PE (1:400; 560074; BD Pharmingen; San Diego, CA),
anti-RORc-APC (1:400; IMG-6275G; IMGENEX; San Diego,
CA) and anti-Foxp3-PE.Cy7 (1:400; 25–5773; eBiosciences; San
Diego, CA) following the instructions specified in the manufac-
turer’s protocol. In parallel, isotype-matched control antibodies for
the different fluorochromes were used as negative controls and
spleen samples as positive control. Spleen samples were also used
to determine the gates for CD3+ and CD3+CD4+cells. In order to
perform the quantification of the total number of cells, a known
volume of fluorescence beads (CytoCountTM, S2366, DakoCyto-
mation) was added and mixed with each sample. Finally, cells were
acquired using a FACScalibur or FACsCanto flow cytometer
(Becton Dickinson; San Jose, CA), and the results were analysed
using FlowJoH software. Quantification of total number of cells
was performed following the methodology specified in the
manufacturer’s data-sheet (CytoCountTM, S2366, DakoCytoma-
tion). Spinal cords from each animal in both sham and EAE
groups were analyzed separately. Only in the case of the
transcription factors study spinal cords were pooled (a minimum
of three animals per clinical score).
Tissue processing for histological analysis
Animals processed for immunohistochemistry were sacrificed
under deep anaesthesia (ketamine/xylazyne) as previously de-
scribed and perfused intracardially with 4% paraformaldehyde in
0.1 M PBS (pH 7.4)+5% sucrose. Spinal cords (cervical and
thoracic part) were dissected out immediately, postfixed for 4 h at
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4uC in the same fixative, and series of parallel longitudinal sections
(40 mm thick) were obtained using a Leica VT 1000 S vibratome.
Series were stored at 220uC in the Olmos antifreeze solution until
their later use.
Single immunohistochemistry
Some parallel free-floating vibratome sections were processed
for the visualisation of different subtypes of lymphocytes: CD3 for
all T-cell populations and CD4 for T-helper cells. After
endogenous peroxidase blocking with 2% H2O2 in 70% methanol
for 10 min, sections were blocked in 0.05 M Tris-buffered saline
(TBS), pH 7.4, containing 10% foetal calf serum, 3% bovine
serum albumine (BSA) and 1% Triton X-100 for 1 h. Afterwards,
sections were incubated overnight at 4uC with either anti-CD3
(1:500; A0452; Dakopatts, Denmark) or anti-CD4 (1:1000;
MCA55G; AbD Serotec) antibodies diluted in the same blocking
solution. Sections incubated in media lacking the primary
antibody were used as negative controls, and spleen sections as
positive control. After washes with TBS +1% Triton, sections were
incubated at room temperature for 1 h with either biotinylated
anti-mouse secondary antibody (1:500; BA-2001; Vector Labora-
tories, Inc; Burlingame, CA) or biotinylated anti-rabbit secondary
antibody (1:500; BA-1000; Vector Laboratories, Inc; Burlingame,
CA). After 1 h in streptavidin-peroxidase (1:500; SA-5004; Vector
Laboratories, Inc; Burlingame, CA), the reaction was visualised by
incubating the sections in a DAB kit (SK-4100; Vector
Laboratories, Inc; Burlingame, CA) following the manufacturer’s
instructions. Finally, sections were mounted on slides, some of
them counterstained with toluidine blue, dehydrated in alchohol
and after xylene treatment, coverslipped in DPX. Sections were
analysed and photographed with DXM 1200F Nikon digital
camera joined to a Nikon Eclipse 80i microscope.
Double immunohistochemistry
Double-immunolabelling was carried out by firstly processing
the sections with either CD3 or CD4 immunolabelling as
described above, but using, as secondary antibodies, AlexaFluorH
488-conjugated anti-rabbit (1:1000, A-21206; Molecular Probes)
in the case of CD3, or AlexaFluorH 555-conjugated anti-mouse
(1:1000, A31570; Molecular Probes) in the case of CD4. After
several washes, these sections were incubated overnight at 4uC
with either rabbit anti-Iba1 (1:3000; 019–19741; Wako), mouse
anti-CD4 (1:1000; MCA55G; AbD Serotec), rabbit anti-Tbet for
demonstration of Th1 cells (1:1000; sc-21003; Santa Cruz
Biotechnology), rabbit-anti-Foxp3 for demonstration of T-reg cells
(1:2000; sc-28705; Santa Cruz Biotechnology) or rabbit anti-
RORc for demonstration of Th17 cells (1:2000; ab78007;
AbCam) followed, by AlexaFluorH 555-conjugated anti-mouse
(1:1000; A31570; Molecular Probes) in the case of CD4, and by
AlexaFluorH 488-conjugated anti-rabbit (1:1000, A-21206; Mo-
lecular Probes) for Iba1. In the cases of Tbet, Foxp3 and ROR-c
after the primary antibody, sections were incubated with
biotinylated anti-rabbit secondary antibody (1:500; BA-1000;
Vector Laboratories, Inc; Burlingame, CA) followed by Strepta-
vidin-Cy3 (1:1000; PA-43001; Amersham). Finally, sections were
mounted on slides, dehydrated in graded alchohol and cover-
slipped in DPX. Sections were analysed using a fluorescence
Nikon Eclipse E600 confocal microscope and photographed with a
Leica DMIRE 2 confocal camera.
Tissue processing for ELISA analysis
For ELISA studies, animals at different clinical scores (3 animals
per score) were anesthetised using ketamine/xylazyne solution, as
previously described, intracardially perfused with phosphate buffer
solution (PBS) and samples corresponding to the part between the
cervical and the thoracic spinal cord (C7–T2 levels) snap frozen in
liquid nitrogen and stored at 280uC. Total protein were extracted
by solubilization of spinal cords in Lysis buffer containing 250 mM
HEPES (pH7.4), 1% Igepal, 5 mM MgCl2, 1.3 mM EDTA,
1 mM EGTA, 1 mM PMSF and protease and phosphatase
inhibitor cocktails (1:100, Sigma Aldrich). Following solubilization,
samples were clarified by centrifugation at 13000 rpm for 5 min
and the supernatant retained. Total protein concentration was
determined with a commercial Pierce BCA Protein Assay kit
(23225, Thermo Scientific) using manufacturer’s protocol. Protein
lysates were stored aliquoted at 280uC until their posterior used
for ELISA.
Cytokines ELISA
Cytokine ELISA kits for IFN-c (KRC4021, Invitrogen), IL10
(KRC0101, Invitrogen), IL17 (E90063Ra, USNC Life Science
Inc), IL21 (E91688Ra, USNC Life Science Inc) and Quantikine
ELISA kit for IL22 (M2200, R&D Systems) were used according
to the manufacturer’s instruction. A standard curve was generated
with each assay with the limit of detection for IFN-c = 13 pg/ml,
IL10 = 5 pg/ml, IL17 = 6.1 pg/ml, IL21 = 5.8 pg/ml and IL22
= 3.2 pg/ml.
CD3+ cell quantification
For CD3+ cell quantification, a total of three EAE-induced
animals per clinical score and three sham were used. Analysis was
performed using one entire longitudinal section of the cervical
spinal cord, per animal. This section corresponds to a medial
section containing both the grey and the white matter areas. Each
section was photographed at 4x using a DXM 1200F Nikon digital
camera joined to a Nikon Eclipse 80i microscope, and pictures
taken were merged using Adobe Photoshop software. The total
number of CD3+ cells per section was counted by the use of
analySISH software.
Statistical analysis
All statistics along the study were performed using the Graph
Pad PrismH software. Either standard two-tailed, unpaired
Student’s-T test, to compare two specific groups of animals, or
one-way ANOVA with Tukey’s post-hoc test, to compare between
the different scores, were used to determine statistically significant
differences.
Results
MBP-induced Lewis rat developed the first signs of EAE around
10 days post-immunisation (dpi), displaying loss of tail tonus (score
0.5). Afterwards, during the induction phase, animals progressively
presented tail paralysis (score 1) followed by hindlimb paraparesis
(score 2) until reaching the maximum clinical symptomatology at
score 3 (approximately around 12–14 dpi) when animals showed
complete hindlimb paralysis. Animals remained at this maximum
score for 1–2 days and afterwards spontaneously started to
recover. During the recovery phase, animals progressively
improved their mobility achieving scores 2R and 1R, and around
21 dpi, were completely recovered (score 0R) and no clinical signs
were observed. During the post-recovery phase (28 dpi, 32 dpi,
40 dpi and 90 dpi), the animals did not show any visible sign of
disease.
It is important to highlight here that, as we have done in
previous works [3,4], animals to be analysed for flow cytometry,
ELISA and immunohistochemistry were selected not based on the
days post-immunisation, but rather exclusively according to their
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clinical score, during the induction, peak and recovery phases.
This criterion has demonstrated to be more useful because, as
already stated in our previous studies, the variability among
animals in the same score, if any, is very low.
CD3+ cells
The study of sections immunolabelled for CD3 revealed that
there was no presence of T-lymphocytes in the spinal cord of sham
animals (Fig. 1A). In contrast, in EAE animals, from score 0.5, few
little round CD3+ cells were observed in the parenchyma (Fig. 1B).
The number of CD3+ cells increased progressively during the
induction phase, mainly accumulating around blood vessels
(Fig. 1C, D and J), reaching their maximal at scores 2 and 3. At
score 3, CD3+ cells in addition to remain in close proximity to
blood vessels, were also found extensively distributed throughout
the parenchyma, in both the grey and the white matters (Fig. 1E).
During the recovery phase, from score 2R to 1R, although the
number of CD3+ cells remained without significant changes
(Fig. 1J), the density of cells around blood vessels increased,
whereas a progressive decrease in the number of CD3+ cells
Figure 1. Dynamics of CD3+ cells. Immunohistochemistry for CD3 in the cervical spinal cord of sham animals (A) and in EAE animals during the
induction (B–D), peak (E), recovery (F–H) and post-recovery phases (I). Arrows in B and I point to the few CD3+ cells observed in these scores. Note the
progressive increase in the number of CD3+ cells in both the grey (GM) and white matter (WM) during the induction and peak phases and the
maintenance of these cells during the recovery phase. Bar scale = 30 mm. Inserts in C–I represents panoramic views showing the localization of CD3+
cells in the spinal cord. Bar scale = 100 mm. J) Histogramme showing analysis of CD3+ cell density observed in the different clinical scores (ANOVA and
Tukey’s post-hoc test *p#0.05 with respect to sham and score 0.5; $ p#0.05 with respect to score 2, 3, 2R and 1R).
doi:10.1371/journal.pone.0027473.g001
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within the parenchyma of the cervical spinal cord was observed
(Fig. 1F and G). The major part of positive cells at score 0R was
accumulated in the surroundings of blood vessels of both grey and
white matters (Fig. 1H). Quantitative analysis showed that at score
0R, the number of CD3+ cells apparently decreased, although the
value did not reach statistical significance.
During the post-recovery phase, at score 0R–40 dpi, a high
reduction of CD3+ cells was observed (Fig. 1J) although few
perivascular CD3+ cells were still detected in the cervical spinal
cord (Fig. 1I). At score 0R–90 dpi, CD3+ cells completely
disappeared (Fig. 1J).
CD3+CD4+cells
The number and proportion of CD4+ cells within the gated
CD3+ cell population was analysed by flow cytometry along the
different phases of EAE evolution (Fig. 2A). In contrast to sham
animals, where no presence of CD3+CD4+ cells was found, in
EAE animals, from score 1 in the induction phase, a high number
of CD4+T-helper lymphocytes was observed (Fig. 2B). The
number of CD3+CD4+ cells remained without significant changes
along the induction and peak phases and also at score 2R, and
only significantly decreased from score 1R. During the post-
recovery phase, at score 0R–32dpi, an important and marked
decrease in the number of these cells was found (Fig. 2B and C). In
addition to the number of cells, we also analysed the proportion of
CD3+CD4+ cells. It should be noted that CD4+ T-cells
represented around 70% of the total CD3+ lymphocytes
(Fig. 2D). This high percentage of CD4+ T-cells was maintained
without significant changes at the different scores analysed during
the induction, peak and recovery phases (Fig. S1). Only during the
post-recovery phase, at score 0R–32dpi, a slight decrease in the
proportion of CD4+ cells was observed (Fig. 2B and D).
In all phases analysed, around 90% of CD3+CD4+ cells showed
a CD45RC- phenotype, characteristic of effector/memory
lymphocytes, and only few CD45RC+ naı¨ve lymphocytes were
detected (Fig. 2E).
Subtypes of CD4+ T-lymphocytes
The different subpopulations of CD4+ T-helper lymphocytes
were determined by flow cytometry using specific antibodies
against lineage-specific transcription factors. After gating in the
CD3+ cell population, combinations of CD4 with Tbet (for Th1
cells), RORc (for Th17 cells) and Foxp3 (for T-regulatory cells)
were analysed.
Th1 cells. As shown in Fig. 3, in EAE animals, a progressive
increase in the number of CD4+Tbet+ cells in the gated CD3+ cell
population was detected from score 1, reaching the maximum value at
scores 2 and 3 (Fig. 3A and B). From score 2R, a marked decrease in
the number of CD4+Tbet+ cells was observed (Fig. 3A and B). This
population of CD4+Tbet+ cells represented, at scores 2 and 3, around
7% of CD3+ lymphocytes (Fig. 3C). During the post-recovery phase
(score 0R–28dpi and score 0R–40dpi) Th1 cells were absent (Fig. 3A
and B). As expected, levels of IFNc were high during the inductive
phase and peak and decreased during the recovery phase (Fig. 3D).
Double immunohistochemistry demonstrated the presence of
Th1 cells in the spinal cord mainly accumulated around blood
vessels (Fig. 3E–G, Fig. S2).
Th17 cells. In EAE animals, some CD4+RORc+ cells were
observed during the induction phase, the peak and at score 2R in
the recovery phase (Fig. 4A and B). The number of CD4+RORc+
cells highly increased from score 1R in the recovery phase, reaching
the maximum value at score 0R (Fig. 4B). During the post-recovery
phase, an important decrease in the number of CD4+RORc+ cells
was detected (Fig. 4B). In terms of percentage of this population, it
should be noted that, whereas during the induction and peak phases
the subpopulation of CD4+RORc+ lymphocytes represented
around 7% of CD3+ T-cells, from score 1R in the recovery phase
the percentage of these lymphocytes increased until a value of
around 50% at score 0R (Fig. 4C). During the post-recovery phase,
a decrease in the percentage of these cells was found although levels
remained higher than those observed during the induction and peak
phases (Fig. 4C). In addition to CD4+RORc+ cells, our analysis also
demonstrated the presence of a population of CD4-RORc+ cells
(less than 10%) (Fig. 4A).
The study of double immunolabelled sections indicated the
presence of CD4+RORc+ cells mainly accumulated around blood
vessels in the spinal cord of EAE animals (Fig. 4D–F, Fig. S2).
T-regulatory cells. As shown in Fig. 5, during the induction
phase, the peak, and at score 2R in the recovery phase, only few
CD4+Foxp3+ cells within the gated CD3+ population were
observed (Fig. 5A and B). From score 1R during the recovery
phase, a substantial increase in the number of CD4+Foxp3+ cells
was observed until score 0R, when the maximum quantity of these
cells was found (Fig. 5A and B). The number of these
CD4+Foxp3+ cells significantly decreased during the post-
recovery phase from score 0R–28dpi to score 0R–40dpi (Fig. 5B).
This population of CD4+Foxp3+ cells represented less than 10%
of CD3+ T-cells at score 1R, and approximately 15% at score 0R
(Fig. 5C). Remarkably, at score 0R–28dpi, the proportion of these
cells remained unchanged, though the total number of
CD4+Foxp3+ cells decreased considerably (Fig. 5C). It was not
until score 0R–40dpi when the proportion of this population
underwent a substantial decline (Fig. 5C).
Double immunofluorescence analysis showed the accumulation
of T-reg cells around blood vessels (Fig. 5D–F).
Expression of Th17 and T-reg related cytokines
The analysis of different cytokines such as IL17, IL21 and IL22
commonly related with the subpopulation of Th17 lymphocytes, as
well as IL10, related with both Th17 and T-reg populations were
studies using ELISA assays. Our results indicated that interest-
ingly, there are no changes in IL10 and IL17 protein levels along
Figure 2. CD4 T-helper cells. A) Dot-plots exemplifying how the analysis of CD3+CD4+ cells was performed. CD3+ T-cells were gated (circle in left
dot-plot) and the percentage and number of CD3+CD4+ cells were analysed in this gated population (square in right dot-plot). Spleen samples were
used to determine CD3+ and CD3+CD4+ gates. B) Representative dot-plots showing the dynamics of the CD3+CD4+ cell population (square) in both
sham and EAE animals during the induction phase (score 1 and 2), peak (score 3), recovery phase (score 2R, 1R and 0R) and post-recovery phase
(score 0R–32dpi). Note that in relation to shams, there is an important and persistent population of CD3+CD4+ cells in EAE animals. C and D)
Histogrammes showing the values corresponding to CD3+CD4+ cell number (C) and relative percentage (D) along EAE evolution (ANOVA and Tukey’s
post-hoc test, *p#0.01 and #p#0.001 with respect to the previous score, $ p#0.05 with respect to score 1 and score 3). E) On the left side,
representative dot-plot of CD3+CD4+ cells of EAE animals. In the middle, representative histogramme where populations of CD45RC- cells (activated/
effector lymphocytes) and CD45RC+ cells (naı¨ve lymphocytes) were defined. Isotype control is represented in grey. On the right, histogramme
showing the values of the percentages of CD45RC- (white columns) and CD45RC+ cells (black columns) in the different phases along EAE evolution
(Student’s-T test, * p#0.0001 when compare CD45RC+ vs CD45RC- in each score). Spinal cords of each animal were analysed separately (from three to
seven animals per group were used).
doi:10.1371/journal.pone.0027473.g002
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Figure 3. Dynamics of Th1 cell population. A) Representative dot-plots of the population of CD4+Tbet+ cells of EAE animals. Dot-plots were
obtained by previously gating in the CD3+ T cell population. Different quadrants were defined by application of the appropriate isotype control. A
minimum of three animals per group was pooled and three replicates per score were analyzed. B and C) Histogrammes showing, respectively, the
values corresponding to the total number and the percentage of CD4+Tbet+ cell population along EAE. Note that CD4+Tbet+ lymphocytes are found
during the induction and peak phases and markedly decreased at score 2R of the recovery phase (ANOVA and Tukey’s post-hoc test, *p#0.05 with
respect to the previous score). D) Histogramme showing the IFNc protein levels detected by ELISA assay at the representative scores during the
induction, peak and recovery phases of EAE (ANOVA and Tukey’s post-hoc test). E–G) Photographs of double immunostained sections showing a
representative CD4+Tbet+ cell found around blood vessels (BV) (arrows point to double-immunolabelled cell). Bar scale = 20 mm.
doi:10.1371/journal.pone.0027473.g003
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Figure 4. Dynamics of Th17 cells. A) Representative dot-plots of CD4+RORc+ cells in the different phases along EAE evolution. Dot-plots were
obtained after gating in the population of CD3+ T-cells. Different quadrants were defined by application of the appropriate isotype control. A
minimum of three animals per group was pooled and three replicates per score were analyzed. The total number and percentage of CD4+RORc+ cells
along the different phases of EAE are represented in histogrammes B and C, respectively. Note that during the recovery and the post-recovery phases,
Th17 Lymphocytes in Acute EAE
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27473
the different phases of the disease (Fig. 6A and B). In contrast, a
decrease in IL21 was found from score 2 of the inductive phase of
EAE showing the lowest levels of expression of this phase at score 3
(Fig. 6C). A slight increase of this cytokine was found during the
recovery phase although it was only at score 1R when the level of
expression was similar to the observed in sham animals.
The analysis of IL22 indicated that levels of this cytokine increased
in the induction phase showing a high level of expression at the peak of
disability (score 3). Subsequently, a marked decrease of IL22 was found
since score 2R in the recovery phase. Like in sham animals, levels of
this protein were undetectable at score 0R (Fig. 6D).
Discussion
In this study a detailed analysis of the different subtypes of T-
helper lymphocytes that infiltrated the CNS along the diverse
phases of the acute EAE model in Lewis rat is performed. Our
results show that during the induction and peak phases, the
number of CD3+ cells increased in close relationship to disease
severity. Nevertheless, during the recovery phase, although clinical
signs decreased, the number of CD3+ lymphocytes remained very
high without significant variations. Even during the post-recovery
phase, some CD3+ cells were still found within the parenchyma of
the spinal cord. Similarly we found that the proportions of CD4+
T-helper cells remained unchanged along the evolution of EAE,
displaying a phenotype of activated/effector cells (CD45RC- cells)
throughout all phases analysed. These findings are striking as
traditionally T-lymphocytes, especially those with a CD4+ T-
helper phenotype, are considered pathogenic cells in EAE. This
assumption is partly due to the capacity of CD4+ lymphocytes to
induce the disease when injected into susceptible animals [24] and
their presence at the peak of the disease in different models of EAE
[18,21,22], and partly due to studies reporting an improvement of
clinical symptomatology of EAE after treatments that produced a
decrease in lymphocyte infiltration [25]. Although in this line, a
decrease in the number of these cells could be also expected during
the spontaneous recovery phase of this acute EAE model,
noticeably, the findings obtained in this study show that the
number of CD4+ T-lymphocytes remained elevated during this
phase. These observations correlate with our previous findings
showing that microglia/macrophages in this EAE model remained
activated also during the recovery and post-recovery phases of this
acute EAE model [3,4], and point towards a cross-talk between
microglia and lymphocyte populations along the evolution of the
disease, not only during the induction and peak, but also during
the recovery phase [26].
It is important to take into account that, CD4+ T-cells comprise
a wide range of subpopulations which not only play pathogenic
functions but also may play regulatory/suppressive roles [7,8,9,27]
that may explain why in our study, these CD4+T cells remained
high also during all the recovery phase. In this sense, by using
lineage-specific transcription factors, we carried out an accurate
study of different subsets of CD4+ T-helper lymphocytes along
EAE evolution, determining the specific temporal pattern of
infiltration of Th1 (Tbet+), Th17 (RORc+) and T-reg (Foxp3+)
cells. These specific transcription factors were shown to regulate
genes encoding the signature cytokines of these different
subpopulations of T-cells. Thus, Th1 cytokines such as IFN-c
and TNF-a are regulated by Tbet [28], Th17 cytokines IL17,
IL22 or IL21 by RORc and cytokines associated with T-reg cells
such as IL10 and TGF-b were regulated by Foxp3 [29]. Our
findings revealed that these different subsets of T-helper
lymphocytes are present in the spinal cord in specific phases
along the course of the disease. In our study it was clearly
demonstrated that the number of Th1 lymphocytes
(CD3+CD4+Tbet+ cells) and the expression of the pro-inflamma-
tory cytokine IFNc, parallels the disease evolution, increasing
progressively during the induction phase, reaching the maximum
at the peak of the disease and decreasing thereafter during the
recovery phase.
In parallel to a decrease in Th1 cells, during the recovery phase,
a high increase in Th17 and T-reg cell populations was found.
Th17 cells are commonly considered as a pathogenic population
of lymphocytes, as they have been detected at the onset of EAE in
mice [30], infiltrated the CNS parenchyma after the initial influx
of Th1 lymphocytes [27,31] and, when injected into susceptible
animals, they are able to induce EAE [12,31]. However in our
study, the number of these cells greatly increased at the end of the
recovery phase (from score 1R), peaking at score 0R. One
plausible explanation for these distinct results could be the
differences in the EAE model used. In contrast to the
aforementioned studies describing Th17 cells as pathogenic
lymphocytes, which used relapsing-remitting or chronic models
induced in mice, in this study we analysed the acute EAE model
induced in Lewis rats. This model has a unique feature: the
complete and spontaneous recovery, that was absent in both the
relapsing-remitting or chronic models in mice, and whose nature
has not yet been established. Thus, it is reasonable to think that
cells involved in the evolution of this acute model, including Th17
cells, can play different roles in the progressive or chronic models
of EAE. Indeed, this is the first study describing the specific
dynamics of different subsets of T cells in correlation to clinical
symptomatology in an acute EAE model with spontaneous
recovery. Therefore, the pathogenic role attributed to Th17 cells
in mice, could be not applicable to this acute rat model. In fact, the
exact role played by Th17 cells in autoimmunity has been under
active discussion [32], specially after the publication of some
interesting studies providing data that bring in question the
pathogenic potential of IL17, the signature cytokine of Th17 cells.
In one hand IL17 treatment has been shown to induce an
amelioration of experimental autoimmune uveitis in Lewis rats
[33] and, in the other hand, mice with a conditional deletion of
IL17 develop EAE normally [34]. In agreement with this last
statement, the analysis of IL17 protein levels in our study
demonstrated that despite the high increase in Th17 lymphocytes
during the recovery phase, protein levels of this cytokine remained
unaltered along the different phases of EAE, suggesting that may
be IL17 is not the key cytokine secreted by these lymphocytes in
this acute model or that their function is not as relevant as though.
In this way, it has been demonstrated that beyond to produce pro-
inflammatory cytokines such as IL17, Th17 lymphocytes are also
able to secrete anti-inflammatory cytokines such as IL10 [35] with
a suggested beneficial effect specifically in acute EAE in Lewis rat
[36], and others such as IL22 [9] and IL21 whose role in EAE is
still not well established. Addition of IL21 before the onset of EAE
symptoms aggravates the disease [37], but the blockade of IL21/
IL21R pathway induced an enhancement of EAE severity [38,39].
Furthermore, exposure of dendritic cells to IL21 induced an
from score 1R, a great increase in the subpopulation of CD4+RORc+ cells was observed (ANOVA and Tukey’s post-hoc test, *p#0.001 with respect to
the previous score). D–F) Photographs of double immunolabelled sections showing a representative CD4+RORc+ cell (arrow) observed around blood
vessels (BV). Bar scale = 30 mm.
doi:10.1371/journal.pone.0027473.g004
Th17 Lymphocytes in Acute EAE
PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e27473
Figure 5. Dynamics of T-regulatory cells. A) Representative dot-plots of the CD4+Foxp3+ cell population along the different phases of EAE
evolution. Dot-plots were obtained after gating in the population of CD3+ T-cells. Quadrants were defined by application of the appropriate isotype
control. A minimum of three animals per group was pooled and three replicates per score were analyzed. B and C) Histogrammes showing,
respectively, the total number and percentage value of CD4+Foxp3+ cells along the different phases of EAE. Note that although the number of
CD4+Foxp3+ cells decreased at 0R–28dpi, their percentage remained high until score 0R–40dpi (ANOVA and Tukey’s post-hoc test, *p#0.001 with
respect to the previous score). D–F) Photographs of double immunolabelled sections showing a representative CD4+Foxp3+ cell (arrows) found
around blood vessels (BV). Bar scale = 30 mm.
doi:10.1371/journal.pone.0027473.g005
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immature phenotype of these cells [40] that cannot induce T-cell
responses [41,42]. In this regard, it is interesting to highlight that
we have previously reported that parenchymal microglial cells
acquire an immature DC phenotype during the recovery phase,
characterised by the expression of CD1 (an immature marker of
dendritic cells) and MHCs but not co-stimulatory molecules [3].
Thus, we can speculate that cytokines secreted by Th17
lymphocytes during the recovery phase can be involved in the
induction of changes in microglial phenotype during this phase.
Following this hypothesis, we analysed the pattern of expression of
IL10, IL21 and IL22 along the different phases of acute EAE.
Interestingly, in contrast to our initial hypothesis and as already
mentioned for IL17, the pattern of expression of these three
cytokines did not correlate with the presence of Th17, indicating
together that, at list in this acute EAE model, Th17 cells are not
producing IL17, IL10, IL21 or IL22. It is interesting to remark the
marked decrease observed in the levels of IL22 in the initiation of
the recovery phase. This striking result open a new and interesting
way of study pointing to this cytokine as a putative key factor
involved in the evolution of EAE. One possibility is that this
cytokine may drive the inflammatory events occurring during the
inductive and peak phases, and therefore a decrease in IL22
production may lead to stop inflammation and initiate the
recovery. In another hand, also we can argue that certain levels
of this cytokine are required to initiate the recovery phase,
therefore when reach the correct threshold triggers the recovery
mechanisms. Further studies in this sense are however necessary to
completely understand the role played by this cytokine in the acute
EAE model in Lewis rat. At this time, it is also interesting to point
out that in general, there is a lack of information in the literature
regarding the specific pattern of cytokine expression along the
different phases of the different EAE models. Moreover, most
studies linking lymphocytes with the secretion of various cytokines
are based on the isolation of these cells and their subsequent
activation in vitro, results that indicate the ability of these
lymphocytes to produce these cytokines but, as already demon-
strated in this study, does not necessarily implicate that they are
doing the same function in vivo in the CNS. A better
understanding of the real scenario occurring within the CNS
parenchyma in terms of cytokine profile may be very helpful to
understand the processes leading to the resolution and/or
chronicity of this disease in the different animal models.
In addition to the Th17 lymphocyte population, during the
recovery phase we also found a significant increase in the number
of Foxp3+ T-reg cells. Accumulation of these T-regs in the CNS
has already been reported during recovery in mice EAE models
[14,15,43], albeit to our knowledge this is the first study
demonstrating accumulation of Foxp3+ cells within the spinal
cord of acute EAE-induced rats. Some studies have demonstrated
the beneficial role played by these cells in EAE pathogenesis in
mice. As such, injection of Foxp3+ T-reg cells, derived from EAE-
recovered mice or in vitro-expanded, ameliorates EAE symptom-
atology when injected into MOG-induced mice [15,44]. In the
same way, a decrease or inactivation of Foxp3+ cell numbers in
vivo by the use of anti-CD25 antibody treatment, makes these
treated animals more vulnerable to EAE induction [45]. Since we
found the major proportion of T-reg cells during the recovery
phase of EAE, we can speculate that Foxp3+ cells in this model
may play also a role in the resolution of the immune response and
can be one of the critical factors involved in the spontaneous
recovery characteristic of the model.
Noticeably, during the post-recovery phase, although the
number of both Th17 and T-reg cells declined, the proportion
of these cell populations remained high, mostly at score 0R–28dpi.
Figure 6. Cytokine profile along EAE. Histogrammes showing the
IL10 (A), IL17 (B), IL21 (C) and IL22 (D) protein levels along the different
phases of EAE. Note that while IL10 and IL17 cytokines remained
unaltered along EAE evolution (A and B), IL21 levels decreased in score
2, 3 and 2R (C) (Student’s-T test, **p#0.01 and *p#0.05 with respect to
sham; $ p#0.05 with respect to score 1 and 2) and IL22 levels were
higher during the inductive phase and markedly decreased during the
recovery phase (D) (ANOVA and Tukey’s post-hoc test, $ p#0.05 with
respect to sham; *p#0.05 with respect to score 3).
doi:10.1371/journal.pone.0027473.g006
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This long-time permanence suggests that these cells can still play
an active role even after the animals have fully recovered and do
not show any clinical symptom, may be being involved in the
tolerance mechanism that, after EAE induction, renders these
Lewis rats resistant to further immunization with the same antigen
[1].
Several studies have demonstrated that recovery from acute
EAE is commonly associated with apoptotic elimination of
pathogenic lymphocytes [46,47,48,49]. As our findings showed
that when the recovery phase started the number of Th1 cells
abruptly decrease, we hypothesise that this decrease may be due to
an induced apoptotic elimination of these lymphocytes. In fact, we
detected a high amount of apoptotic lymphocytes, especially
during the peak of the disease, in near proximity to microglial cells
(Fig. S3). This hypothesis fits well with our previous findings [3]
showing that during the induction and peak phases, microglial
cells displayed an immature dendritic-cell phenotype (MHC-class I
and II+/CD1+/B7.1-/B7.2-) which may provide an anergic or
apoptotic signal to the Th1-infiltrated lymphocytes [26] and is in
agreement with a recently published study [50] showing that
myeloid-derived suppressor cells, an heterogeneous population of
immature myeloid cells involved in the regulation of immune
responses in tumour microenvironments [51], can induce the
apoptosis of infiltrated T-cells also in a chronic mouse model of
EAE. Nevertheless, we cannot exclude the possibility that the
different T-cell populations observed and their dynamics are the
result of a phenomenon of lymphocytic plasticity, bearing the
interconversion between T-cell subtypes, as has recently been
postulated by some authors [52,53].
Conclusion
In conclusion, we clearly demonstrate in this study that, although
the number of T-lymphocytes inside the spinal cord parenchyma
remains constant along the three main phases of EAE (induction,
peak and recovery) the lymphocytic phenotype along the different
phases undergo major changes. During the induction and peak
phases major part of lymphocytes exhibited a phenotype of Th1
cells, whereas during the recovery and post-recovery phases T-
lymphocytes mainly displayed a phenotype of Th17 or T-reg cells.
Moreover, our results demonstrated a specific cytokine profile along
the different phases of this acute EAE model, which differs from the
described in chronic and relapsing-remitting models, characterized
by no changes of IL10 and IL17 levels, decrease of IL21 on the peak
phase, and high levels of IL22 during the induction and peak phases
that markedly decrease during recovery.
These results suggest that the general view of lymphocyte
infiltration in the CNS as a detrimental process should be reviewed.
Our results demonstrated that it is not a question of presence or
absence of T-cells, but the scenario is more complicated, being
necessary to consider the specific subtype of infiltrated lymphocytes,
their function and the specific interactions that these lymphocytes
established with resident cells within the CNS. Further studies to
analyse these interactions are necessary to understand the specific
role played by these lymphocytes along EAE evolution. In this
context, actions played by secreted cytokines in particular situations
should also be more carefully reviewed.
Supporting Information
Figure S1 A–D) Cells immunolabelled with CD3 and
CD4 were observed at the different scores of EAE
evolution (arrows). Note that, in addition to these double
positive cells, also few CD3+CD4- cells (arrowheads in B and D)
and CD3-CD4+ cells (asteriscs in A, B and C) were also observed.
Bar scale = 30 mm
(TIF)
Figure S2 A–C) Photographs showing the CD4 (A) and
Tbet (B) immunostatining at score 0R. Note that the few
Tbet+ cells did not colocalize with CD4 (arrows in A–C). D–F)
Colocalization between CD4 and ROR-c was found at score 0R
in some cells located near blood vessels (arrows). Bar scale =
30 mm
(TIF)
Figure S3 Apoptotic lymphocytes. A–C) Double immuno-
labelling combining the microglial marker Iba1 and CD4, and
counterstained with DAPI. Iba1+ microglial cells (green) were
observed closely related to apoptotic cells that were identified as
CD4+ lymphocytes (arrows in A, B and C). Bar scale = 20 mm
(TIF)
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